The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and quality control using the procedures defined in CLSI standards CLSI M02, M07, and M11.
Please provide your email address to receive an email when new articles are posted on . Using Clinical and Laboratory Standards Institute, or CLSI, revised breakpoints and omitting extended-spectrum ...
WAYNE, Pa.--(BUSINESS WIRE)--The Clinical and Laboratory Standards Institute announces the publication of its annually updated antimicrobial susceptibility testing (AST) supplement M100—Performance ...
Why mismatched resistance thresholds between CLSI and EUCAST could be masking the true scale of antimicrobial resistance in the environment. How can global standardization fix this problem? Study: ...
This presentation will give an update about easing the administrative burden on the lab to assess compliance with CLSI/FDA breakpoints. Topics addressed included FDA 510(k) approvals, the VITEK® V9.04 ...
Zaynich (zidebactam/cefepime- WCK 5222) has been granted a susceptibility breakpoint of 64 mg/L for around 10 gram negative pathogens showing high resistance rates by the Clinical and Laboratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results